<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Boric acid vaginal suppository: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Boric acid vaginal suppository: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Boric acid vaginal suppository: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140228" href="/d/html/140228.html" rel="external">see "Boric acid vaginal suppository: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57119484"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AZO Boric Acid [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56516592"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-infective Agent, Vaginal</li></ul></div>
<div class="block doa drugH1Div" id="F56513091"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Use for the treatment of bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis is based on studies utilizing boric acid powder compounded in a gelatin capsule for intravaginal use; commercially available boric acid suppositories have not been evaluated for these indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22877600','lexi-content-ref-19704395','lexi-content-ref-14634557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22877600','lexi-content-ref-19704395','lexi-content-ref-14634557'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a58a9640-78bb-4666-92e1-0f6c102e8959">Bacterial vaginosis, recurrent infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis, recurrent infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment is generally not warranted for patients who are asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravaginal:</b> 600 mg once daily at bedtime for 3 to 4 weeks, in combination with or after 7 days of an oral nitroimidazole, followed by suppressive topical antibacterial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84e20dc9-97b5-4cb9-82ce-4493c31bf0d6">Candidiasis, vulvovaginal, caused by <i>C. glabrata</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, vulvovaginal, caused by <i>C. glabrata</i> (off-label use): Intravaginal: </b>600 mg once daily at bedtime for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-14634557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-14634557'])">Ref</a></span>). <b>Note:</b> Reserve for patients with no other clear cause of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41d1ba3a-1885-4af9-9f19-a3005d301d94">Trichomoniasis, refractory or resistant infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichomoniasis, refractory or resistant infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with infection refractory to multiple prior regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-22877600','lexi-content-ref-30575848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-22877600','lexi-content-ref-30575848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravaginal:</b> 600 mg twice daily for 28 days in combination with oral tinidazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575848'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="946c128f-6398-4e83-bb56-6e0bbf8b02a5">Vaginal pH balance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaginal pH balance (OTC labeling): Intravaginal:</b> 1 suppository (600 mg) once daily at bedtime for 7 days; if symptoms persist, may repeat for another week. May be used twice daily if needed.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F56513093"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F56513094"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F56513092"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F56495147"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (Prutting 1998), skin irritation (sexual partner) (Prutting 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal discharge (watery) (Mittelstaedt 2021; Prutting 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local irritation (Mittelstaedt 2021; Prutting 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Burning sensation (Prutting 1998)</p></div>
<div class="block war drugH1Div" id="F56513086"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not take orally; suppositories and compounded capsules are for vaginal use only. Acute toxicity (sometimes fatal) may occur if boric acid is ingested orally (ACOG 2020; Hadrup 2021). Do not use on broken or irritated vaginal mucosa. Discontinue use and contact a health care provider if symptoms persist or worsen or if irritation or burning develop.</p></div>
<div class="block dosfc drugH1Div" id="F58268110"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not all available formulations may be represented in Dosage Forms. Additional boric acid suppository products may be available from other manufacturers/suppliers.</p></div>
<div class="block foc drugH1Div" id="F57119485"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:2em;">Suppository, Vaginal:</p>
<p style="text-indent:2em;margin-left:2em;">AZO Boric Acid: 600 mg (30s)</p></div>
<div class="block adm drugH1Div" id="F56513095"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intravaginal:</b> For intravaginal use only; do not administer orally. Use at bedtime as there may be watery leakage; if used during the day, use with a panty liner.</p></div>
<div class="block use drugH1Div" id="F56513081"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">
<b>Vaginal pH balance:</b> Balance vaginal pH and control odor.</p></div>
<div class="block off-label drugH1Div" id="F56513082"><span class="drugH1">Use: Off-Label: Adult</span><p>Bacterial vaginosis, recurrent infection; Candidiasis, vulvovaginal, caused by Candida glabrata; Trichomoniasis, refractory or resistant infection</p></div>
<div class="block mst drugH1Div" id="F56513080"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Baricitinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Do not take orally; suppositories and compounded capsules are for vaginal use only. Acute toxicity (sometimes fatal) may occur if boric acid is ingested orally (ACOG 2020; Hadrup 2021).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56560191"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56560188"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Progesterone: Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56513083"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients should use reliable contraception during treatment with boric acid vaginal suppositories (ACOG 2020).</p></div>
<div class="block pri drugH1Div" id="F56513084"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of boric acid vaginal suppositories during pregnancy are limited (Acs 2006; Heinonen 1977).</p>
<p style="text-indent:0em;margin-top:2em;">Due to limited human data and lack of animal reproduction studies (Mittelstaedt 2021), vaginal boric acid is only recommended for patients who are not pregnant (ACOG 2020). Agents other than boric acid are recommended for the treatment of bacterial vaginosis or vulvovaginal candidiasis in patients who are pregnant (CDC [Workowski 2021]; IDSA [Pappas 2016]).</p></div>
<div class="block brc drugH1Div" id="F57549641"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Boric acid is present in breast milk (Manakova 2008; Wiley 1907).</p>
<p style="text-indent:-2em;margin-left:2em;">Boric acid concentrations in breast milk may vary based on route of exposure (Manakova 2008; Wiley 1907).</p></div>
<div class="block pha drugH1Div" id="F57549645"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Boric acid has weak bacteriostatic and fungistatic properties when used vaginally (Prutting 1998).</p></div>
<div class="block phk drugH1Div" id="F57549646"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: ~100%, vaginal: limited (up to 6% in uninfected volunteers) (Mittelstaedt 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Renal (Mittelstaedt 2021).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58844940"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Greenwood Healthcare Boric Acid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16530197">
<a name="16530197"></a>Acs N, Bánhidy F, Puhó E, Czeizel AE. Teratogenic effects of vaginal boric acid treatment during pregnancy. <i>Int J Gynaecol Obstet</i>. 2006;93(1):55-56. doi:10.1016/j.ijgo.2005.12.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/16530197/pubmed" id="16530197" target="_blank">16530197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31856123">
<a name="31856123"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 215: vaginitis in nonpregnant patients.<i> Obstet Gynecol</i>. 2020;135(1):e1-e17. doi:10.1097/AOG.0000000000003604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/31856123/pubmed" id="31856123" target="_blank">31856123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AZO.1">
<a name="AZO.1"></a>AZO Boric Acid (boric acid) topical [prescribing information]. Cromwell, CT: I-Health Inc; received January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33485927">
<a name="33485927"></a>Hadrup N, Frederiksen M, Sharma AK. Toxicity of boric acid, borax and other boron containing compounds: a review. <i>Regul Toxicol Pharmacol.</i> 2021;121:104873. doi:10.1016/j.yrtph.2021.104873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/33485927/pubmed" id="33485927" target="_blank">33485927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heinonen.1">
<a name="Heinonen.1"></a>Heinonen OP, Slone D, Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Publishing Sciences Group Inc; 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18987605">
<a name="18987605"></a>Manakova E, Hubickova-Heringova L, Novakova L. Drugs during lactation accenting boron exposure. <i>Neuro Endocrinol Lett</i>. 2008;29(5):631-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/18987605/pubmed" id="18987605" target="_blank">18987605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34561373">
<a name="34561373"></a>Mittelstaedt R, Kretz A, Levine M, et al. Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. <i>Sex Transm Dis</i>. 2021;48(12):e241-e247. doi:10.1097/OLQ.0000000000001562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/34561373/pubmed" id="34561373" target="_blank">34561373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22877600">
<a name="22877600"></a>Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. <i>Sex Health</i>. 2012;9(4):389-391. doi:10.1071/SH11114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/22877600/pubmed" id="22877600" target="_blank">22877600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9812253">
<a name="9812253"></a>Prutting SM, Cerveny JD. Boric acid vaginal suppositories: a brief review. <i>Infect Dis Obstet Gynecol</i>. 1998;6(4):191-194. doi:10.1002/(SICI)1098-0997(1998)6:4&lt;191::AID-IDOG10&gt;3.0.CO;2-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/9812253/pubmed" id="9812253" target="_blank">9812253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704395">
<a name="19704395"></a>Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. <i>Sex Transm Dis</i>. 2009;36(11):732-734. doi:10.1097/OLQ.0b013e3181b08456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/19704395/pubmed" id="19704395" target="_blank">19704395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575848">
<a name="30575848"></a>Salas A, Hamill MM, Tuddenham S. Nitroimidazole resistance in Trichomonas vaginalis infection: a teachable moment. <i>JAMA Intern Med</i>. 2019;179(2):247-248. doi:10.1001/jamainternmed.2018.7241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/30575848/pubmed" id="30575848" target="_blank">30575848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.2">
<a name="Sobel.2"></a>Sobel JD. Bacterial vaginosis: Initial treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 30, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.1">
<a name="Sobel.1"></a>Sobel JD. Candida vulvovaginitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 30, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14634557">
<a name="14634557"></a>Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. <i>Am J Obstet</i>
<i>Gynecol</i>. 2003;189(5):1297-1300. doi:10.1067/s0002-9378(03)00726-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/14634557/pubmed" id="14634557" target="_blank">14634557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7282789">
<a name="7282789"></a>Van Slyke KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. <i>Am J Obstet Gynecol</i>. 1981;141(2):145-148. doi:10.1016/s0002-9378(16)32581-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/7282789/pubmed" id="7282789" target="_blank">7282789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiley.1">
<a name="Wiley.1"></a>Wiley HW. The excretion of boric acid from the human body. <i>J Biol Chem</i>. 1907;3:11-19. http://www.jbc.org/content/3/1/11.full.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/boric-acid-vaginal-suppository-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134822 Version 24.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
